RNLXY
Renalytix plc$3.85 +0.00 (+0.00%)
Oct 27 4:00 PM ET · prev $3.85
1 year
−97.2%
from $137.50 · Oct 27
30 days
−3.8%
from $4.00
52-week range
$1.10–140.63
−97% from high · low Apr 24
Avg volume 20D
3.8K
Sep 30 spike 28.2K
Short interest
🔒 Subscribers only
New fund stakes
0
Q3 2024 13F · 0 exits
Reddit crowd
71°
Bullish · 3 mentions this week
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 31 Short interest jumps 204.2% to 38.5K
- X Aug 14 Short interest falls 99.2% to 327
- X Aug 31 Short interest jumps 349.5% to 1.5K
- X Sep 15 Short interest falls 50.5% to 727
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2024: 0 added (0 new), 1 trimmed or exited.
- TrendRANGE
5% above its 50-day average.
- SocialQUIET
Crowd 71° (bullish) this week from 3 mentions: 3 bullish, 0 bearish. No setup call.
Who's buying
13F· Q3 20240
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | TRIM | $460.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jul 2024Recent actions
| Date | Firm | Rating |
|---|---|---|
| Jul 12, 2024 | HC Wainwright & Co. REITERATE | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2024 Inst.
MORGAN STANLEY — TRIM
2,200 shares ($460.00)
Reddit mentions per day, 14 days
Crowd this week 71° Bullish 3 bullish · 0 bearish
Mentions, 7 days 3 3 in posts · 0 in comments
Recent posts
US Kidney Care National Plan Reinforces $RNLXY Thesis: KidneyIntelX Is the First FDA-Authorized Prognostic Test for Chronic Kidney Disease Progression Risk + Recently Announced Quest Diagnostics Partnership
3 upvotes · 1 comments
US Kidney Care National Plan Reinforces RNLXY Thesis: KidneyIntelX Is the First FDA-Authorized Prognostic Test for Chronic Kidney Disease Progression Risk + Recently Announced Quest Diagnostics Partnership
1 upvotes · 1 comments
US Kidney Care National Plan Reinforces RNLXY thesis. It has the only FDA approved Bioprognostic on the market designed to predict kidney decline. Recently partnered with Quest Diagnostics
1 upvotes · 1 comments
RNLXY recent announced a collab with Quest Diagnostics. This is a comparison to GRAIL ($GRAL) who collaborated with Quest in 2021
5 upvotes · 2 comments